A Phase 4 interventional study of Eldecalcitol and Native Vitamin D in Osteoporosis in Postmenopausal Women, sponsored by Xi'an Honghui Hospital. Completed at 1 site in China. Open to female participants. Per ClinicalTrials.gov, last updated 2025-11-24.
Sponsored by Xi'an Honghui Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.
Among the 87 studies in Osteoporosis with a site in China, this one is the 37th largest by enrollment of the 57 interventional ones that give a count, is one of 8 that started in 2023, is one of 13 in phase 4, and was the 51st registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Sites in China
Ages 45–80 · Women only
Dr. Li Chen · Sites in China
Ages 18+ · Healthy volunteers
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Peking University People's Hospital · Sites in China
Ages 18+ · Healthy volunteers
Wuhan Union Hospital, China · Sites in China
Ages 40+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 120 across the 57 interventional studies, 1,750 across the 30 observational. Of the 33 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 87 have an industry lead sponsor. The 10 most frequent:
Xi'an Honghui Hospital is the lead sponsor of 3 studies on the registry; 1 is open to participants now.
Xi'an Honghui Hospital has 1 study filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Osteoporosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT07895082Phase 3Shanghai University of Traditional Chinese MedicineQuanduzhong Capsules for Primary Osteoporosis | 2027-04-15 |
| NCT07474571Peking University People's HospitalEvaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging | 2026-12-01 |
| NCT07165158The First Affiliated Hospital of Xiamen UniversityThe Effect of Semaglutide on Bone Health | 2026-12-31 |
| NCT06379243The Seventh Affiliated Hospital of Sun Yat-sen UniversityDevelopment and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 87 studies in Osteoporosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective:
To compare the bone mineral density (BMD) change under the treatment of denosumab with eldecalcitol or native vitamin D in postmenopausal women with osteoporosis on bone mineral density.
Secondary objective:
To compare the efficacy of denosumab with eldecalcitol or native vitamin D treatment in postmenopausal women with osteoporosis on bone turnover markers, serum PTH, serum calcium, serum phosphorus, muscle mass, muscle strength, body balance ability, and quality of life.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Denosumab (subcutaneous injection 60mg/6 months) combined with ELD (oral 0.75μg/day) for 12 months.
Drug: Eldecalcitol · Drug: Denosumab
Denosumab (subcutaneous injection 60mg/6 months) combined with native vitamin D (oral 800IU/day) and Calcium (oral 600mg/day) for 12 months.
Drug: Native Vitamin D · Drug: Denosumab · Drug: Calcium
the same as arm descriptions.
the same as arm descriptions.
the same as arm descriptions.
the same as arm descriptions.
the percent change from baseline at month 12 in BMD at the lumbar spine L1-4.
the percent change from baseline at month 12 in BMD at the lumbar spine L1-4.
Time frame: 12 months
the percent change from baseline at month 6 in BMD at the lumbar spine L1-4.
the percent change from baseline at month 6 in BMD at the lumbar spine L1-4.
Time frame: 6 months
the percent change from baseline at each visit in BMD at the femoral neck and total hip.
the percent change from baseline at each visit in BMD at the femoral neck and total hip.
Time frame: 12 months
the percent change from baseline at each visit in serum CTX,P1NP,PTH.
the percent change from baseline at each visit in serum CTX,P1NP,PTH.
Time frame: 12 months
the score change from baseline at month 6 and month 12 in quality of life by 16-item Assessment of Health-Related Quality of Life in Osteoporosis,(ECOS-16).
the score change from baseline at month 6 and month 12 in quality of life by 16-item Assessment of Health-Related Quality of Life in Osteoporosis,(ECOS-16). The scale ranges from 16 to 80, with higher scores meaning higher risk.
Time frame: 12 months
Incidence rate of new vertebral fracture and new non-vertebral fracture in 1 year.
Incidence rate of new vertebral fracture and new non-vertebral fracture in 1 year.
Time frame: 12 months
the change from baseline at month 6 and month 12 in body balance ability by measuring One Leg Standing (OLS).
the change from baseline at month 6 and month 12 in body balance ability by measuring One Leg Standing (OLS).
Time frame: 12 months
the change from baseline at month 6 and month 12 in limb skeletal muscle content by DXA.
the change from baseline at month 6 and month 12 in limb skeletal muscle content by DXA.
Time frame: 12 months
the change from baseline at month 6 and month 12 in physical function by measuring 5 times chair stand.
the change from baseline at month 6 and month 12 in physical function by measuring 5 times chair stand.
Time frame: 12 months
the change from baseline at month 6 and month 12 in muscle strength by measuring handgrip strength.
the change from baseline at month 6 and month 12 in muscle strength by measuring grip strength.
Time frame: 12 months
the change from baseline at month 6 and month 12 in body balance ability by measuring 10 Meter Walk (10MW).
the change from baseline at month 6 and month 12 in body balance ability by measuring 10 Meter Walk (10MW).
Time frame: 12 months
the change from baseline at month 6 and month 12 in body balance ability by measuring Timed Up and Go (TUG).
the change from baseline at month 6 and month 12 in body balance ability by measuring Timed Up and Go (TUG).
Time frame: 12 months
Plan to share: No
Ran from Aug 2023 to primary completion in Jul 2025, 22 months.
Of 55 non-industry phase 4 interventional studies under Osteoporosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 71. This study's 22 months is below that.
Counting every sponsor, half of 65 studies reached it within 46 months; a quarter within 29 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Eldecalcitol
Xi'an Honghui Hospital